S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:BNTX

BioNTech (BNTX) Stock Price, News & Analysis

$92.97
+1.27 (+1.38%)
(As of 03/27/2024 ET)
Today's Range
$90.80
$93.56
50-Day Range
$88.96
$100.29
52-Week Range
$85.21
$131.52
Volume
378,014 shs
Average Volume
697,110 shs
Market Capitalization
$22.10 billion
P/E Ratio
22.57
Dividend Yield
N/A
Price Target
$133.77

BioNTech MarketRank™ Stock Analysis

Analyst Rating
Hold
2.27 Rating Score
Upside/​Downside
29.5% Upside
$120.40 Price Target
Short Interest
Bearish
1.30% of Float Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.16mentions of BioNTech in the last 14 days
Based on 24 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.00) to ($1.27) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.85 out of 5 stars

Medical Sector

486th out of 939 stocks

Biological Products, Except Diagnostic Industry

76th out of 151 stocks

BNTX stock logo

About BioNTech Stock (NASDAQ:BNTX)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It also develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I clinical trial to treat multiple solid tumors; and BNT312, which is in Phase I clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase II clinical trial to treat ovarian cancer and Phase I clinical trial to treat multiple solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BNTX Stock Price History

BNTX Stock News Headlines

Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
BioNTech Full Year 2023 Earnings: Misses Expectations
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
BioNTech Q4 Net Profit Plummets
See More Headlines
Receive BNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
3/28/2024
Next Earnings (Estimated)
5/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:BNTX
Employees
6,133
Year Founded
2008

Price Target and Rating

Average Stock Price Target
$120.40
High Stock Price Target
$171.00
Low Stock Price Target
$90.00
Potential Upside/Downside
+43.9%
Consensus Rating
Hold
Rating Score (0-4)
2.27
Research Coverage
10 Analysts

Profitability

Net Income
$1.01 billion
Pretax Margin
31.06%

Debt

Sales & Book Value

Annual Sales
$3.82 billion
Cash Flow
$5.07 per share
Book Value
$92.17 per share

Miscellaneous

Free Float
192,083,000
Market Cap
$22.10 billion
Optionable
Optionable
Beta
0.23

Social Links

The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Dr. Ozlem Tureci M.D. (Age 57)
    Co-Founder, Chief Medical Officer & Member of Management Board
    Comp: $895.64k
  • Mr. Jens H. Holstein (Age 61)
    CFO & Member of Management Board
    Comp: $943.18k
  • Dr. Sierk Poetting Ph.D. (Age 51)
    MD, COO & Member of Management Board
    Comp: $990.72k
  • Mr. Ryan Richardson (Age 45)
    Chief Strategy Officer, MD & Member of Management Board
    Comp: $478.61k
  • Mr. Sean Marett (Age 59)
    Chief Business Officer, Chief Commercial Officer & Member of Management Board
    Comp: $918.33k
  • Dr. James Timothy Patrick Ryan Ph.D. (Age 49)
    Chief Legal Officer & Member of the Management Board
  • Mr. Zach Taylor
    Senior Vice President of Corporate Development & Strategy
  • Dr. Oliver Henning Ph.D.
    Senior Vice President of Operations
  • Dr. Sebastian Kreiter M.D.
    Senior Vice President of Immunotherapy & Preclinical Research
  • Mr. Siegbert Kloos
    Senior Vice President of Global R&D Digital, Datand Informatics

Should I Buy BioNTech Stock? BNTX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of BioNTech was last updated on Sunday, March 24, 2024 at 3:10 PM.

Pros

Here are some ways that investors could benefit from investing in BioNTech SE:

  • BioNTech has a growing pipeline of drugs, including advanced oncology programs with multiple trials in progress. This diversification reduces dependency on any single product or market segment, potentially mitigating risks associated with a narrow product portfolio.
  • The company's stock price has shown resilience and potential for growth, with a current valuation that presents a value opportunity for investors compared to industry averages. This could indicate a favorable entry point for those seeking long-term growth potential.
  • Recent developments, such as the launch of innovative mRNA vaccine candidates like the Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine, demonstrate BioNTech's commitment to addressing evolving healthcare needs and staying at the forefront of biopharmaceutical innovation.
  • BioNTech's expansion of its pipeline to include various modalities and promising candidates in advanced clinical trials positions the company as an attractive target for potential partnerships or acquisitions by larger pharmaceutical firms seeking to bolster their portfolios and address upcoming patent cliffs.
  • The company's CEO, Prof. Ugur Sahin, highlighted significant progress in advancing the pipeline and achieving positive clinical data in various programs, indicating a strong leadership focus on innovation and growth in the biotechnology sector.

Cons

Investors should be bearish about investing in BioNTech SE for these reasons:

  • While BioNTech's pipeline expansion is promising, the biopharmaceutical industry is highly competitive and subject to regulatory uncertainties, clinical trial outcomes, and market dynamics that could impact the company's future growth prospects and financial performance.
  • The potential for regulatory challenges or delays in the approval process for new drug candidates could introduce uncertainties and risks to BioNTech's revenue projections and market positioning, affecting investor sentiment and stock performance.
  • Market volatility and macroeconomic factors, such as shifts in healthcare policies, global health crises, or changes in investor sentiment towards biotechnology stocks, may influence BioNTech's stock price and overall market performance, leading to fluctuations in investment returns.
  • BioNTech's dependence on successful clinical trials, regulatory approvals, and commercialization of new products for revenue growth exposes the company to inherent risks associated with drug development, including potential setbacks, competition, and market acceptance challenges.
  • Investors should consider the company's debt-to-equity ratio, liquidity position, and overall financial health when evaluating investment opportunities, as these factors can impact BioNTech's ability to fund research and development initiatives, expand operations, and navigate industry challenges.

BNTX Stock Analysis - Frequently Asked Questions

Should I buy or sell BioNTech stock right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BioNTech in the last twelve months. There are currently 1 sell rating, 5 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BNTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BNTX, but not buy additional shares or sell existing shares.
View BNTX analyst ratings
or view top-rated stocks.

What is BioNTech's stock price target for 2024?

10 Wall Street research analysts have issued 1-year price targets for BioNTech's shares. Their BNTX share price targets range from $90.00 to $171.00. On average, they anticipate the company's stock price to reach $120.40 in the next year. This suggests a possible upside of 29.5% from the stock's current price.
View analysts price targets for BNTX
or view top-rated stocks among Wall Street analysts.

How have BNTX shares performed in 2024?

BioNTech's stock was trading at $105.54 at the beginning of 2024. Since then, BNTX stock has decreased by 11.9% and is now trading at $92.97.
View the best growth stocks for 2024 here
.

Are investors shorting BioNTech?

BioNTech saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 3,080,000 shares, an increase of 5.5% from the February 29th total of 2,920,000 shares. Based on an average daily trading volume, of 689,800 shares, the days-to-cover ratio is currently 4.5 days. Currently, 1.3% of the company's shares are sold short.
View BioNTech's Short Interest
.

When is BioNTech's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 13th 2024.
View our BNTX earnings forecast
.

How were BioNTech's earnings last quarter?

BioNTech SE (NASDAQ:BNTX) released its quarterly earnings results on Monday, November, 6th. The company reported $0.67 EPS for the quarter, beating the consensus estimate of ($0.59) by $1.26. The firm earned $895.30 million during the quarter, compared to analyst estimates of $850.50 million. BioNTech had a trailing twelve-month return on equity of 4.60% and a net margin of 24.26%. BioNTech's quarterly revenue was down 74.1% on a year-over-year basis. During the same quarter in the prior year, the company posted $7.04 EPS.

Is BioNTech a good dividend stock?

BioNTech (NASDAQ:BNTX) pays an annual dividend of $1.53 per share and currently has a dividend yield of 0.00%. The dividend payout ratio is 37.14%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for BNTX.

What guidance has BioNTech issued on next quarter's earnings?

BioNTech updated its FY 2024 earnings guidance on Tuesday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $3.2 billion-$3.2 billion, compared to the consensus revenue estimate of $4.2 billion.

What is Ugur Sahin's approval rating as BioNTech's CEO?

33 employees have rated BioNTech Chief Executive Officer Ugur Sahin on Glassdoor.com. Ugur Sahin has an approval rating of 89% among the company's employees. 81.0% of employees surveyed would recommend working at BioNTech to a friend.

What other stocks do shareholders of BioNTech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioNTech investors own include Moderna (MRNA), Pfizer (PFE), Inovio Pharmaceuticals (INO), Tesla (TSLA), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Johnson & Johnson (JNJ), Zoom Video Communications (ZM) and Advanced Micro Devices (AMD).

When did BioNTech IPO?

BioNTech (BNTX) raised $251 million in an IPO on Thursday, October 10th 2019. The company issued 13,200,000 shares at $18.00-$20.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink served as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers.

Who are BioNTech's major shareholders?

BioNTech's stock is owned by many different institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.66%), Primecap Management Co. CA (2.00%), Harding Loevner LP (1.66%), Flossbach Von Storch AG (1.49%), Capital World Investors (0.39%) and Voloridge Investment Management LLC (0.25%).

How do I buy shares of BioNTech?

Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does BioNTech have any subsidiaries?
The following companies are subsidiares of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, BioNTech RNA Pharmaceuticals, BioNTech Real Estate GmbH & Co. KG, BioNTech Real Estate Verwaltungs, BioNTech Research and Development, BioNTech Small Molecules, BioNTech USA Holding, JPT, TheraCode JPT, and reBOOST Management.
Read More
This page (NASDAQ:BNTX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners